Search research articles
Contact Us
Filters
Showing results (11-20 of 60) with videos related to
Page
of 6
Sort By:
Journal of Medicinal Chemistry
|
March 13, 2010
Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor
Vijaykumar G Pawar, Martin L Sos, Haridas B Rode, et al.
Molecular Cancer
|
October 12, 2011
L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer
Verena Tischler, Marco Pfeifer, Silke Hausladen, et al.
Plos One
|
January 30, 2010
Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling
Martin Peifer, Jonathan Weiss, Martin L Sos, et al.
Cell Reports
|
August 16, 2014
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors
Martin L Sos, Rebecca S Levin, John D Gordan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2012
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants
Johannes M Heuckmann, Hyatt Balke-Want, Florian Malchers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2011
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Johannes M Heuckmann, Michael Hölzel, Martin L Sos, et al.
Journal of Medicinal Chemistry
|
June 19, 2013
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design
André Richters, Julia Ketzer, Matthäus Getlik, et al.
JTO Clinical and Research Reports
|
March 20, 2026
Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies
Montse Sanchez-Cespedes, William W Lockwood, Kenichi Suda, et al.
Plos One
|
December 17, 2008
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET)
Roland T Ullrich, Thomas Zander, Bernd Neumaier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2017
Mechanisms of Primary Drug Resistance in <i>FGFR1</i>-Amplified Lung Cancer
Florian Malchers, Meryem Ercanoglu, Daniel Schütte, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 60) with videos related to
Sort By:
Page
of 6
Journal of Medicinal Chemistry
|
March 13, 2010
Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor
Vijaykumar G Pawar, Martin L Sos, Haridas B Rode, et al.
Molecular Cancer
|
October 12, 2011
L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer
Verena Tischler, Marco Pfeifer, Silke Hausladen, et al.
Plos One
|
January 30, 2010
Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling
Martin Peifer, Jonathan Weiss, Martin L Sos, et al.
Cell Reports
|
August 16, 2014
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors
Martin L Sos, Rebecca S Levin, John D Gordan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2012
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants
Johannes M Heuckmann, Hyatt Balke-Want, Florian Malchers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2011
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors
Johannes M Heuckmann, Michael Hölzel, Martin L Sos, et al.
Journal of Medicinal Chemistry
|
June 19, 2013
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design
André Richters, Julia Ketzer, Matthäus Getlik, et al.
JTO Clinical and Research Reports
|
March 20, 2026
Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies
Montse Sanchez-Cespedes, William W Lockwood, Kenichi Suda, et al.
Plos One
|
December 17, 2008
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET)
Roland T Ullrich, Thomas Zander, Bernd Neumaier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2017
Mechanisms of Primary Drug Resistance in <i>FGFR1</i>-Amplified Lung Cancer
Florian Malchers, Meryem Ercanoglu, Daniel Schütte, et al.
Page
of 6